Cambridge Healthtech Institute’s 6th Annual
Patient Engagement, Enrollment and Retention through Communities and Technology
Patient Centric Approaches to Optimize Clinical Trials and Participant Engagement
February 20-21, 2019
Enrollment planning, patient recruitment and a more patient-centric approach to study planning and execution are critical to drug development programs and garner a lot of attention by study teams. However, once the hard work of identifying and recruiting
a trial subject has been accomplished they must be retained and remain in compliance. Retention of patients throughout the life of a clinical trial is essential to have complete data sets for your analysis and subsequent filings. There are strategies,
tools and data-driven techniques such as social media platforms and mobile technology, empowered patient communities, and a more informed patient population that need to be understood and engaged. CHI’s 6th Annual “Patient Engagement, Enrollment and Retention through Communities and Technology” will cover the topics one should consider when planning and strategically implementing a patient retention plan in the digital age.
Final Agenda
Wednesday, February 20
11:30 am Registration Open (Convention Level)
12:30 pm BRIDGING LUNCHEON PRESENTATION: Leveraging Analytics and the Patient Voice to Optimize Patient Recruitment & Retention Campaigns
Robert Loll, Senior Vice President,
Business Development & Strategic Planning, Praxis Communications, LLC
As the world becomes more and more digital, it is important to tap into the endless amounts of data and conversations being shared on the Internet to glean patient insights and understanding. As we have lunch, we’ll explore case studies and discuss
how our industry can utilize data and analytics to craft and optimize efficient and effective patient-centric enrollment campaigns.
1:10 Coffee and Dessert Break in the Exhibit Hall (Plaza International Ballroom)
2:10 Plenary Keynotes(Regency PQ)
3:20 Booth Crawl & Refreshment Break in the Exhibit Hall, Last Chance for Exhibit Viewing (Plaza International Ballroom)
4:05 Chairperson’s Remarks
Robert Loll, Senior Vice President, Business Development & Strategic Planning, Praxis Communications, LLC
4:10 CO-PRESENTATION: From Patient Voices to Real Solutions - Industry Examples Guided by Online Patient Interactions
Kevin Hudziak, Consultant, Innovation Lead, Patient Experience
and Design Innovation, Eli Lilly & Co.
Leigh Anne Naas, Community Manager, Patient Experience and
Design Innovation, Eli Lilly & Co.
Lilly maintains an active social media presence with @LillyTrials to ensure we are continually engaging with and listening to patients and caregivers to gain insights into the clinical trial journey. We will provide real world examples of how we have
converted those insights into actions. These actions are centered around the Lilly TrialGuide ecosystem.
4:40 CASE STUDY: Insights from the Introduction of a Patient App to Improve Clinical Trial Engagement and Retention
Christie Fry, Therapeutic Area Lead Oncology, Patient & Investigator
Relations, AbbVie
AbbVie introduced a pilot program for patient apps to improve compliance and retention in a few clinical trials. From this pilot program, we learned how an app can help and where we need to improve in the development of future apps. I will present real
data from our experience which led to important insights. These will be helpful for others that are considering apps for use in clinical trials.
5:10 Patient Engagement & Retention “It’s Not Just About the Patient"
Claire Russell, Executive Director, Patient Experience, PRA Health Sciences
To design a truly patient-centered trial requires the development of a comprehensive patient persona- this includes an understanding of anyone that surrounds the patient. Personas tell us when, where and how to engage with a potential study participant.
Removing study participation barriers extends to those that care for the study participant. While the patient is at the heart of the study – it’s their care circle that impacts the participants decision to enroll in a study.
5:40 Creating a Platform to Connect Directly with Patients Now and in the Future
Maura Snyder, MBA, Director, Patient Engagement Strategy & Portfolio,
Janssen
More than 90% of study participants never learn about study-specific results and recent data show 81% of patients want their own data and results above all other information. There is an opportunity to create a direct interface between the patient and
sponsor to stay connected and share information. This interface also empowers patients by providing access to data, information, research opportunities to create engagement and a long-term partnership build on transparency, trust and awareness.
6:10 – 7:10 Networking Reception (Regency Foyer)
Thursday, February 21
7:15 am Registration Open (Convention Level)
7:45 BREAKFAST PRESENTATION: A User's Perspective into a Unified Imaging and EDC Approach (Regency P)
Troy Schneider, Director, Imaging Strategy, Medidata
Sarah Halek, Head, Innovation Design, ICON Medical Imaging
Come hear from a client on how using an imaging management technology on a unified platform considers the entire clinical trial process, providing configurable, intelligent workflows that complements the users and aligns to protocols, automating de-identification,
edit checks, and workflow management, thereby reducing clinical trial timeline, cost, and risk. The platform ensures that correct data is presented to the right users at the right time, eliminating data reconciliation tasks and bringing visibility
and access.
8:15 Session Break
8:20 Chairperson’s Remarks
Michael Stadler, CEO & Co-Founder, Clariness
8:25 Incorporating the Patient Voice into Drug Development & Gaining Buy-In from Leadership on Patient-Centricity Efforts
Beth Zaharoff, Senior Director, Patient Focused Engagement
and Partnerships, TESARO
Engaging
patients – people who know what it’s like to live with the diseases that our protocols hope to enroll – can help to improve study feasibility, enhance convenience, create greater relevance and build commitment. This presentation
will share how our Clinical Operations department made changes to incorporate the patient voice into the work that we do. Equally important, the presentation will share strategies for gaining support from senior leadership. The audience will have
concrete examples to take back to their organizations.
8:55 Virtual Trials & Remote Trials: Efficiencies and Challenges
Antonieta Sosa, Director, Clinical Innovation, Janssen
& Tine Lewi, PhD, MBA, Scientific Director, Janssen R&D, Clinical Innovation
The concept of virtual (site-less) and remote trials may seem like an efficient method to conducting a clinical trial, and in many ways, it is. There are however, many internal challenges we face as sponsors to discuss and address. Given that we continue
facing challenges with recruitment and enrollment, site activations, etc., discussions around novel trial conduct is essential.
9:25 CO-PRESENTATION: Applying a Consistent Patient-Centered Framework for Patient Insight and Engagement Tools
Michele Teufel, Patient
Engagement Lead, Clinical Operations, AstraZeneca
Sandra Smyth, Director, Central Feasibility and Recruitment Group, AstraZeneca
This presentation will review a consistent Patient-Centered Framework and offer a discussion on various patient insight sources to inform protocol design. In addition to learning about protocol design this insight is used to shape the patient engagement
tools for support during the conduct of study. Discussion will include an analysis of the insights used and the impact on the conduct of studies.
9:55 Bridging the Empathy Gap: A Human-Centric Approach to Engagement
Heather Swech,
MBA, Head, Marketing, Patient Recruitment & Retention, Bioclinica
Building lasting relationships with patients and caregivers requires a holistic view that considers the entire patient experience. Through deep understanding and insights, our online communities and programs, support and empower patients and caregivers,
by providing ongoing engagement, tools and resources throughout their study journey and beyond. The result is an authentic, trusted partnership for continuous interaction and feedback. Patients who engaged through our communities were approximately
1/3 more likely to be retained in the trial.
10:25 Networking Coffee Break (Sponsorship Opportunity Available) (Regency Foyer)
11:10 Chairperson’s Remarks
Kyle Hogan, Director, eClinical Solutions, Clinical Ink
11:15 iSTEP: First of Its Kind Smart Trial and Engagement Program Implemented in Janssen Clinical Trials
Jason LaRoche, Clinical
Innovation Leader, Janssen Research & Development
This talk will share a flexible platform designed to accommodate the unique needs and complexities of individual studies with the core features of patient app, kit tracking and smart packages. We will share preliminary results of a first Phase II
study with Alzheimer’s patients, and discuss the benefits experienced in the first in-clinic use of a novel smart trial and engagement platform. The sharing of lessons learned from this first in-clinic experience will provide valuable guidance
in how to approach patient engagement with novel technologies.
11:45 Proven Digital Enrollment Programs for Serious Diseases
Sandra Shpilberg,
MBA, CEO, Seeker Health
Finding participants for clinical studies in serious diseases, such as rare diseases or oncology, can be akin to finding needles in a haystack. Given that patients have transitioned online to seek disease, drug and clinical trial information, those
needled haystacks are now online. This session will provide the participants with an advanced understanding of how to use social and digital technologies to master patient engagement and accelerate drug development for medicines for serious diseases.
12:00 pm Working Together to Understand the Needs of Patients
Mark Evans, Managing Director, Faze - Havas Lynx
Clinical trials are complex, difficult experiences involving uncertainty, uncomfortable procedures, multiple stakeholders, agencies, vendors and healthcare professionals. How often do we work together as a group to create a connected solution? Is
there a better model for collaboration to benefit our studies and our patients?
12:15 Transition to Shared Sessions
Chairperson’s Remarks (continued from morning session)
Kyle Hogan, Director, eClinical Solutions, Clinical Ink
12:20 Focus on the Worst? A Weak-link Approach to Improving Site Performance and Accelerating Clinical Trials
Angelique Hopkins, Director, Clinical Trial Analytics, Business Insights and Analytics, Bristol-Myers Squibb Company
There are weak link sports (soccer) and strong link sports (basketball), the best method for improving performance in each situation depends on whether investing in the worst
component of a team or the greatest strength on a team makes the biggest difference. For years the preferred method for accelerating clinical trials and improving site performance has been to focus on the highest performing sites. Using trial
simulation and modeling techniques, we can see how a “weak link’ approach to site performance (focusing middle and lower tier sites) may be a better although less intuitive method for increasing performance and accelerating timelines.
12:50 INTERACTIVE PANEL: Moving from Technology Indigestion to Workable Solutions
Moderator: David Vulcano, MBA, Vice President, Research Compliance & Development, HCA
Stephanie Abbott, PharmD, Clinical Research Program Director, Western
Washington Medical Group
Jeewa Perera, CEO, Champ IT Solutions
Brenda Yanak, Former Global Head, Specimen Strategy
and Innovation, Q2 Solutions a Quintiles Quest Joint Venture; Former Precision Medicine Lead, Pfizer
Matt Moyer, MBA, Director, Clinical Supply Technology, Merck
Multiple technologies are advancing healthcare delivery each and every day. This not only pertains to better utilizing both data at rest and data in motion, but also pertains to communication technologies breaking down the traditional boundaries
of medicine. As clinical trial site operations are often dwarfed by the larger healthcare delivery ecosystem, how can pharma leverage that already-developing ecosystem so that they don’t have to recreate the wheel?
- What technologies are out there right now that are underutilized by pharma in clinical trials?
- What regulatory or operational issues need to be either “myth busted” or challenged to make this happen?
1:20 Transition to Lunch
1:25 LUNCHEON PRESENTATION: The Secret to Unlock Adoption of eClinical Solutions
Jeff Lee, President,
eCOA & Patient Engagement, CRF Bracket
1:55 Closing Remarks
2:00 SCOPE Summit 2019 Adjourns